Parrish Richard K, Campochiaro Peter A, Pearson P Andrew, Green Ken, Traverso Carlo E
Ophthalmic Surg Lasers Imaging Retina. 2016 May 1;47(5):426-35. doi: 10.3928/23258160-20160419-05.
To compare elevated intraocular pressure (IOP) management and outcomes among patients with diabetic macular edema who received fluocinolone acetonide (FAc) implants versus sham-control treatment and explore the prior ocular steroid exposure impact on IOP outcomes.
Best-corrected visual acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study charts or electronic VA testers. Goldmann applanation tonometry was used to measure IOP.
Elevated IOP was more common in FAc-versus sham control-treated patients. Medication, and less often trabeculoplasty or surgery, was used to lower IOP without affecting VA outcomes. No patient treated with 0.2 µg/day FAc who received prior ocular steroid required IOP-lowering surgery.
Elevated IOP may occur following FAc implant receipt; however, in the present study, it was manageable and did not impact vision outcomes. Patients previously treated with ocular steroid did not require IOP-lowering surgery following 0.2 µg/day FAc implant administration. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:426-435.].
比较接受氟轻松丙酮化物(FAc)植入物治疗的糖尿病性黄斑水肿患者与假对照治疗患者的眼压升高管理及预后,并探讨既往眼部类固醇暴露对眼压预后的影响。
使用早期糖尿病性视网膜病变研究图表或电子视力测试仪测量最佳矫正视力(BCVA)。采用Goldmann压平眼压计测量眼压。
与假对照治疗的患者相比,接受FAc治疗的患者眼压升高更为常见。使用药物降低眼压,小梁成形术或手术的使用频率较低,且不影响视力预后。接受过眼部类固醇治疗且每日接受0.2μg FAc治疗的患者均无需进行降低眼压的手术。
植入FAc后可能会出现眼压升高;然而,在本研究中,眼压升高是可控的,且不影响视力预后。既往接受过眼部类固醇治疗的患者在每日给予0.2μg FAc植入物后无需进行降低眼压的手术。[《眼科手术、激光与视网膜成像》。2016;47:426 - 435。]